BioSpace News Archive

Theralink Technologies, a precision oncology molecular profiling company with a patented, novel phosphoprotein-based assay for breast cancer announced early results showing actionability and clinical utility for its commercial CLIA assay.

OncoTEX Inc., an oncology company developing first-in-class cancer pharmaceuticals that are tumor localizing, exhibit low side effects, target both drug-sensitive and drug-resistant solid tumors, and are MRI-detectable; today announced its novel cancer-fighting drug candidate, OxaliTEX, has been issued a new U.S. patent.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2021 results on Thursday, March 24, 2022, after the market close.

The American Diabetes Association® (ADA) is thrilled to announce the recipients of the 2022 National Scientific and Health Care Achievement Awards.

KIYATEC today announced that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions.

AMRA’s recent research, performed in collaboration with Daiichi Sankyo and the National Center of Neurology and Psychiatry (NCNP) in Japan, will be presented at the 2022 MDA Clinical & Scientific Conference scheduled for March 13 - 16.

Growing demand for advanced nanoparticle instruments and rise in government investments in research & development activities in the biotechnology and pharmaceutical sectors are among the major factors expected to drive market revenue growth.

The global AI in pharmaceutical market size is expected to be worth around USD 9.24 billion by 2030 from valued at USD 905.91 million in 2021 with a CAGR of 29.4% from 2021 to 2030.